THV-01 / TheraVectys - LARVOL DELTA

Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART). (clinicaltrials.gov) - P1/2; N=38; Completed; Sponsor: Theravectys S.A.; Active, not recruiting ➔ Completed

Clinical • Trial completion